Teleflex has entered into agreements to sell the its Acute Care, Interventional Urology and OEM businesses to two buyers, Intersurgical with respect to Acute Care and Interventional Urology, and Montagu and Kohlberg with respect to OEM, for a combined total of $2.03 billion in cash.
The transactions, which were approved by Teleflex’s board, are expected to be completed in the second half of 2026, subject to customary regulatory approvals and other closing conditions.
Under the terms of the agreements, Teleflex will receive proceeds of approximately $1.5 billion for its OEM business and $530 million for its Acute Care and Interventional Urology businesses, in each case subject to certain closing adjustments. On a combined basis and subject to certain closing adjustments, Teleflex will receive net proceeds of approximately $1.8 billion after tax.
Teleflex primarily intends to use the net proceeds to return significant capital to shareholders through share repurchases and pay down debt, enhancing its financial flexibility to support its growth strategy.
